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INTRODUCTION 
 
This is a Prospective study of Gestational Trophoblastic Diseases 
from one of the largest maternity centers of South Asia – Institute of 
Obstetrics and Gynecology of Madras Medical College, Chennai. This is 
a tertiary referral center in South India giving tertiary care to the people 
from the state of Tamilnadu and also the neighbouring states of Andra 
Pradash and Karnataka. This study was conducted over a period of one 
year covering Ninety Patients. 
Gestational trophoblastic neoplasms (GTN) are proliferative as 
well as degenerative disorders of placental elements and includes 
complete (or) partial hydatidiform mole (90%), invasive mole 5.8% 
which could also be metastatic villous (or) avillous choriocarcinoma. (1-
2%) and placental site tumor (1-2%), GTD is a discrete pool of 
epidemiological and clinicopathological entities. Therefore, every 
geographical region should be studied separately. The Indian 
subcontinent is under reported for this disease. Hence this analysis comes 
from one of the largest maternity center of India. 
In this study we have analyzed the epidemiological factors and 
clinical presentation of molar pregnancy and compared the changing 
trends in the clinical presentation. 
GESTATIONAL / TROPHOBLASTIC / DISEASE 
 
Gestational Trophoblastic Disease 
(Principles and Practice of Gyanecology, Oncology – 3rd Edition) 
Ross.S, Berkowitz and Donald P. Goldstein 
 
 
GTD are one of the rare Human Malignancies that are highly 
curable with chemotherapy even with widespread metastasis. It is a 
heterogenous neoplastic disorders arising from the placental trophoblastic 
tissue after a normal or abnormal fertilization, with varying potential for 
local invasion and metastasis. 
 
There are four main types of gestational trophoblastic disease. These are:- 
 
1. Hydatidiform Mole:- 
  Complete 
  Partial 
2. Persistent  / Invasive gestational trophoblastic disease 
3. Choriocarcinoma 
4. Placental site trophoblastic tumors. 
 
These diseases are characterished by distinctive tumor marker – B 
subunit of Human Chorionic gonadotrophins except placental site 
trophoblastic tumor by Human placental lactogen. 
 
Trophoblasts are specialized epithelial cells derived from the outer 
most layer of the blastocyst that originates in early embryonic 
differentiation. On the basis of morphological, Immunophenotypical and 
functional studies trophoblasts are classified into 3 detective population. 
 
1. Cyto trophoblast 
2. Syncytio trophoblast 
3. Intermediate trophoblast 
 
In early gestation cytotrophoblast differentiate along villous and an 
extra villous pathway. On the villous surface cytotrophoblast differentiate 
into syncytotrophoblast – a poly nucleated structure with complete loss of 
proliferative activity. The second pathway of cytotrophoblast 
differentiates in the placental bed as the intermediate trophoblast which 
infiltrate the deciduas, the myometrium and the arteries of the 
implantation site and establish materno fetal circulation. 
 
 
 
Hydatidiform Mole:- 
 
 Hydatidiform mole (The term hyd means water and refers to the 
fact that HM are shaped like water droplets) Characterized by a hydropic 
swelling of the chorionic villi and trophoblastic proliferation. It is 
classified as a complete hydatidiform mole and partial hydatidiform mole 
on the basis of histopathological features and karyotype (Table:1). 
 
 
Complete Hydatidiform Mole: 
 Complete mole lack identifiable embryonic (or) fetal tissues and 
the chorionic villi exhibit generalized hydatidiform swelling and diffuse 
trophoblastic hyperplasia. Most complete hydatidiform moles are 
cytogenetically diploid usually have a 46xx karyotype and the molar 
chromosomes are entirely of paternal origin. Complete moles appear to 
arise from an ovum that has been fertilized by a haploid sperm, which 
then duplicates its own chromosomes and the ovum nucleus may be 
either absent (or) inactivated. Most complete moles have a 46xx 
chromosomal pattern / 10% have a 46xy Karyotype. Chromosomes in a 
46xy; also appear to be entirely of paternal origin, but in this 
circumstance an apparently empty egg is fertilized by two sperm38. 
 
Partial Hydatidiform Mole (ACS – 2007) 
 
 Partial Hydatidiform mole develops when two sperm fertilize a 
normal egg, these contains some fetal tissue. But this tissue is often 
mixed in the trophoblastic tissue. It is important to know that no viable 
fetus is being formed. Partial hydatidiform mole occurs when an ovum 
with haploid set of chromosomes is fertilized by two spermatozoa that 
carry either of the sex chromosomes. It results in a zygote with a 69 
chromosomes (triploid) with extra set (haploid) set of chromosomes 
derived from the father (69xxy, 69xxx, Occasionally 69xyy). 
 
Histopathological and cytogenetic features of complete and partial mole 
and choriocarcinoma. 
 
TABLE-1 
 
Characteristic Complete 
Mole 
Partial Mole Choriocarcinoma
 
Karyotype 
 
Paternal Origin 
46xx (90%) 
46xy (10%) 
 
Maternal / 
Paternal 
69xxy (58%) 
69xyy (2%) 
69xxx (40%) 
 
Aneuploidy 
 
 
 
 
Fetal (or) 
Embryonic 
tissue 
 
Absent 
 
Present 
 
- 
 
Hydatidiform 
Swelling of 
Chorionic villi 
 
Diffuse 
 
Focal 
 
Absent 
 
 
Trophoblastic 
Hyperplasia 
 
Diffuse 
 
Focal 
 
Diffuse Necrosis 
Hemorrhage 
Scalloping of 
Chorionic villi 
 
Absent 
 
Present 
 
- 
 
 
Trophoblastic 
stromal 
inclusions 
 
Absent 
 
Present 
 
- 
 
 
Invasive Mole:  
 
 An invasive mole (formerly known as chorioadenoma destruens) is 
a hydatidiform mole that penetrates the muscular wall of the uterus 
(myometrium). These develop in about 20% of women who have had a 
complete mole removed by curettage. The risk of developing these in 
women with complete mole in increased if. 
 
9 There is a long time (more than 4 months) between the time 
periods had stopped and treatment. 
9 The uterus has become very large 
9 The women is older than 40 years 
9 The women has had GTD in the past 
 
Invasive moles can be complete (or) partial, but complete moles 
invades much more often than partial mole. These moles sometimes 
disappear on their own, but most require treatment with chemotherapy. In 
15% cases the tumor spreads through the blood stream (metastasis) to 
other sites usually lungs. Morphologically, an invasive mole is 
distinguishable from choriocarcinoma by the presence of villi which are 
generally absent in choriocarcinoma. Cyto genetically invasive moles are 
mostly diploid and some are aneuploid. 
 
Choriocarcinoma:- 
 
 Choriocarcinoma is a malignant form of GTD, invasive neoplasm 
of the trophoblastic epithelium of the placenta. It is characterized by 
masses of cells invading adjacent tissues and penetrating vascular spaces 
(Microscopically, the neoplasm to composed of an avillous invasive 
proliferation of syncytoio  trophoblasts and cytotrophoblasts surrounded 
by necrosis and haemorrhage. Although choriocarcinoma most often 
develop from a complete hydatidiform mole, it can occur after a normal 
pregnancy (or) abortion. 
 
Malignant transformation in GTD involving a series of genetic 
changes including activation of oncogenes and inactivation of tumor 
suppressor genes. Choriocarcinoma is more likely to spread to organs 
away from uterus. Rarely choriocarcinoma. Can develop in other parts of 
the body in both men and women. These are not related to pregnancy. 
They may develop in the ovaries, testicle, chest (or) abdomen. These 
nongestational choriocarcinoma tends to be less responsive to 
chemotherapy and has a less favourable prognosis than gestational 
choriocarcinoma. 
 
 
 
Placental Site Trophoblastic Tumor: 
 
 Placental site trophoblastic tumor is an uncommon but important 
variant of GTN that consists predominantly of intermediate trophoblast 
and a few syncytial elements. These tumors produce small amounts of 
HCG and human placental Lactogen relative to their mass, and tend to 
remain confined to the uterus, metastasizing late in their course. In 
contrast to other trophoblastic tumors, placental site tumors are relatively 
insensitive to chemotherapy. High cure rates can be achieved with early 
diagnosis and surgical resection. Intensive combination chemotherapy 
may achieve complete remission in patients with metastatic disease, 
particularly when the interval from the Antecedent pregnancy is less than 
4 years. 
 
Persistent Gestational Trophoblastic Tumor:- 
 
 Locally invasive GTN develops in 15% of patients after evacuation 
of a complete mole and infrequently after other gestations. These patients 
usually present clinically with one (or) more of the following. 
 
 
1. Irregular vaginal bleedingTheca Lutein cysts 
2. Uterus subinvolution (or) asymmetric enlargement 
3. Persistently elevated serum HCG levels 
 
 
 
After molar evacuation, persistent GTN may exhibit the histologic 
features of either hydatidiform mole (or) choriocarcinoma. After a non 
molar pregnancy,however persistent GTN  always has the histological 
pattern of choriocarcinoma. 
 
The current staging system for GTN combines both Anatomic staging 
and a prognosting scoring system. 
 
Revised FIGO 2000 Staging 
 
Staging of Gestational Trophoblastic Neoplasia 
 
 
Stage I 
 
Confined to Uterine 
corpus 
 
Stage II 
 
Metastasis to pelvis & 
vagina 
 
Stage III 
 
Metastasis to Lung 
 
Stage IV 
 
Distant Metastasis 
 
 
 
Scoring system (Revised FIGO) based on Prognostic factors. 
 
  
0 
 
1 
 
2 
 
4 
 
 
Age 
 
<40 
 
>40 
 
- 
 
- 
 
 
Antecedent Pregnancy 
 
Mole 
 
Abortion 
 
Term 
 
 
 
Intervel months from 
index pregnancy  
 
<4 
 
4-6 
 
7-12 
 
>13 
 
 
 
Pretreatment serum 
HCG (IU / l) 
 
<103
 
103-<104
 
104-<105
 
>105 
 
 
Largest tumor size 
(including uterus) 
 
- 
 
3cm -<5cm 
 
>5cm 
 
 
 
 
Site of metastasis 
 
Lung 
 
Kidney/Spleen 
 
Gastrointestinal 
liver 
 
Brain 
 
Previous failed 
chemotherapy  
 
- 
 
- 
 
Single drug 
 
2 (or) more 
drugs 
 
Number of Metastasis 
 
- 
 
1-4 
 
5-8 
 
>8 
 
  
 
In orders to stage and allot a risk factor score – Patient diagnosis is 
represented by eg. Stage II: 4, Stage IV:9. The stage and score will be 
allotted for each patients. 
 
The total score  <4 – Low risk 
   5-7 – Middle risk 
   >8 – High risk 
 
A prognostic scoring system reliably predicts the potential for resistance 
to chemotherapy and to assist in selecting appropriate chemotherapy. 
REVIEW OF LITERATURE 
 
 
Gestational trophoblastic disease comprise a group of interrelated 
disease including complete and partial molar pregnancy, invasive mole, 
placental site trophoblastic tumor and choriocarcinoma that have varying 
propensities for local invasion and metastasis (Berkowitz and 
P.Goldstein)2. 
 
Gestational trophoblastic disease is among the rare human tumors 
that can be cured even in the presence of wide spread dissemination 
(Norak 14th Edition)38. 
 
Incidence:- 
 
 Estimates of the incidence of GTD vary dramatically in different 
region of the world (Novak 14th edition)38. The frequency of molar 
pregnancy in Asian countries is 7 to 10 times greater than the reported 
incidence in North American (or) Europe where as hydatidiform mole 
occurs in Taiwan in one per 125 pregnancies, the incidence of molar 
gestation in the United States is about one per 1500 live births. (Williams 
J Hoskins 3rd Edition)46. 
 
The incidence of disease in higher in the eastern countries than the 
west (Shaw). It is suggested that GTD occurs especially in rice eaters. 
(Jeffcoate 5th edition)30. 
 
As per a study by B.W.L. Tham et al in BJOG June 200339, there is 
little epidemiological data from the Indian subcontinent, with the 
exception of a reported rate of choriocarcinoma of 19.2 / 1000 
pregnancies, from India. But an Indian study by Kumar  N et al29 
published in medical science monitor in 2003 October from New Delhi 
state that the incidence of GTD was 1.31 / 1000 live births and one per 
967 pregnancies (including live birth, still birth, spontaneous abortions & 
MTP). 
 
One study from Japan by Matsui et al states the incidence of 
hydatidiform mole /1000 live birth was constant from 1974 to 1990, 
while it decreased significantly after 1991. (chi (2) – test for trend, 
P<0.0001). The incidence of complete mole also decreased. 
 
A reported study by Cheah PL et al from malayasia states that 
hydatidiform molar pregnancy has the highest prevalence among Indians. 
A similar finding by B.W.L. Tham et al in BJOG39 states that Asian 
women are increased risk of having molar pregnancies. 
 
A Singapore study by Hancock BW et al, the incidence of 
gestational trophoblastic disease in the Asian Population was 1.95 times 
higher than in the Non Asian population. (1/387 live births Vs 1/752 live 
births). 
 
These regional differences in the frequency of hydatidiform mole 
have been attributed to genetic and environmental factors, (or) the 
interaction of both. This under lines the need for region specific 
epidemiological and etiological study of GTD. Some predisposing factors 
– such as early Menarche, parity, age at first pregnancy, interval between 
previous pregnancies, malnutrition and socioeconomic status generally 
have a geographical specific characters. 
 
On the other hand Asian descent has been reported as a risk factor 
for GTD. This indicates that emphasis on detailed study of GTD and its 
follow up in Asian regions may help in revealing its geographical 
distribution, in a clearer way. (Kumar et al medical science monitor – 
2003)29. 
 
Age:- 
 
 Maternal age older than 35 years has consistently been shown to be 
risk factor for complete mole. Ova from older women may be more 
susceptible to abnormal fertilization. In one study, the risk for complete 
mole was increased 2 fold for women older than 35 years and 7.5 fold for 
women older than 40 years. (Novak 14th Edition)38. 
 
 In a study by Berkowitz et al24, the risk of having a complete molar 
pregnancy increases with advanced maternal age, women older than 40 
have 5 to 10 fold greater risk of having a complete molar gestation. 
 
 A study from clinical Obstetrics Gynaecology 2007, by Donald P. 
Goldstein et al shows that increasing age is the best established risk 
factors for complete molar pregnancy, women over 40 years of age 
having a 5-10 fold higher risk than younger women. Because of the 
higher number of pregnancies in younger women, however most 
complete moles occur in women under 35. Maternal age has not been 
associated with risk of partial molar pregnancy.  
 
 The Following are the various studies on maternal age of GTD  
 
Greatest number of GTD in those 
Age above 35years (or) under 20 
years 
- Talati et al, Karachi47. 
The age specific incidence of 
Complete mole – Major peak in 
those of 35 years and over, 
between 35-39 years – relative 
risk,  2.5 >40 years – RR was 9.8. 
- Fajardo AM et al, Abu Dhabi 
Mean age for Gestational 
Trophoblastic Disease was 29.2 
years  
- Figueira LM et al, Caracas,  
Venezuela, 2006. 
Greatest Number of GTD cases 
occurred mainly among 20-34 
years  
- Shi Y F, Chen XJ et al, China, 
2005 
The incidence of GTD is higher in  
Women below 20 years and above 
39 years  
- Loukovaara M et al, 2001, 
Finland18
Majority of patients are multipara 
40 years of old.  
- CISSE CT et al, Dakar, 200417
Excess of molar pregnancies in the 
Extreme maternal age group 
- Tham B.W. et al, Singapore, 
200339
The mean age for both types of 
HM 
Was 28 years 
- Osamor JO et al, Nigeria, 
200240. 
Majority of patients between 20 to 
25 years 
- Kumar et al, India, 200329. 
 
 
A study from Milan Italy by DICINTIO E et al show that different 
frequency in the various classes of age is seen through out the world. This 
is due to the various ages of maximum fertility in various country (Kumar 
et al, India). The frequency of malignant complications was remarkably 
high in age superior (or) equal to 40 years, high multipara (CISSE CT et 
al – Dakar, 2004)17. 
Antecedent Pregnancy:- 
 
Abortions:- 
 
It is believed that poor obstetric histories associated with increased 
fetal wastage may increase the risk of GTN (Shakuntala Chhabra et al, 
India, 2003). Abortion was associated with modest increased risk of GTD 
in at least seven studies with relative risk ranging from 1.1 to 3.3 (Andrea 
Alteeri et al, 2003, Lancet). 
 
 The risk of both complete and partial molar pregnancy is increased 
in women with a history of prior spontaneous abortion (Berkowitz et al)12 
But a study from Vietnam by Hamar et al in 1996 showed a relative risk 
of 0.3 for a history of induced abortions but no associations for 
spontaneous abortions. 
 
 However the association, if any between the no of abortions & 
same subtypes of GTD could be due to the fact some previous abortions 
could have been undiagnosed GTD, that the increased the risk of a 
subsequent GTD. 
Previous Molar Pregnancy: 
 
 Women with prior molar gestation have a 1% risk of repeat mole, 
approximately 10 times the risk of molar pregnancy in the general 
population (Donald P.Goldstein et al)42, Seventeen out of 21 invasive 
moles (80.9%) were found in multiple abortions and mechanical 
interference in form of check curettage, which probably implicates 
repeated the mechanical interference in the conversion of a mole in to a 
invasive mole (Kumar N et al)29. 
 
When a patient had a molar pregnancy she is at an increased risk of 
having a molar gestation in subsequent pregnancies. After one molar 
pregnancy, the risk of having molar disease in a future gestation is about 
1%. Therefore for any subsequent pregnancy, it seems prudent to 
undertake the following approach. (Novaks, 14th edition)38. 
 
1. Perform pelvic ultrasound examination during the first trimester to 
confirm normal gestational development. 
2. Obtain an HCG measurement 6 weeks after completion of 
pregnancy to exclude occult trophoblastic neoplasia. 
Previous Pregnancies: 
 
 The effect of reproductive history on the risk of GTD remains 
unclear. Atleast three cases control studies in GTD showed a relative risk 
of between 0.6 and 1 for parous women compared with nulliparous 
women (Brenton LA et al, La Veechia et al, Parazzini F et al)41, but two 
other studies reported no association (Matsuura J et al). A separate 
Analysis for CHM and PHM showed a decrease in risk with number of 
births for both diseases, although the trend is reduced risk was only 
significant for PHM (Parazzini F et al) 41. With respect to 
choriocorcinoma a case control study showed a relative risk above unity 
for parous women, although this association was significant only for 
more than 5 births/ relative risk 5.2). However, since GTD are strongly 
associated with pregnancy, the choice of an adequate comparison group is 
difficult.  
 
Blood Group:- 
 
 Women belonging to blood group – A are susceptible to this 
disease, but the reason is not known (Shaw 13th edition). But study by 
Bassaw B et al. The incidence was greatest in patients with blood group 
O. Women with Group A (or) AB blood seemed to have a high risk for 
HM compared with women with blood group B (or) O. (Relative Risk 0.9 
to 4.8). The data also suggested a higher risk for persistent GTD and for 
CHM compared with PHM. (La Vecchia C et al, Parazzini F et al) 41, 
When the combination of different maternal and paternal blood group or 
considered an increased risk was evident for HM for women with group 
A blood and men with group O or A compared with all other 
combinations. (relative risk 1.1 to 2.8 AM. Epidanmol. 1985) 36. 
 
Oral contraceptives: 
 
 The study by Costa & Dolyle et al, the risk ratio for oral 
contraceptive use were 0.69 and 0.71 respectively. Use of oral 
contraceptives was generally associated with an increased risk of GTD, 
with a relative risks ranging from 1.1 (La Vecchia C et al)36 2.6 (Brenton 
LA et al). The risk generally increased with duration of use. 
 
 In largest case control study on Hydatidiform mole (Parazzini F         
et al)41 which included 268 cases the relative risk was 1.7 for 1 year of 
use (or) longer. A relative risk of about 2 was reported for more than 4 
years of use for both CHM (Parazzini F 2002)41 and PHM (Berkowitz et 
al)2. For choriocarcinoma the relative risk ranged from 2 to 6.4 for ever 
use compared with never use. Only one study reported a relative risk for 
long duration of use (2.8 for >7years of use, (Palmer JR et al, 1999). 
 
The incidence of post molar GTN has been reported to be increased 
among patients who used oral contraceptives before gonodotrophin 
remission. However data from both the NETDC and the Gynaecologic, 
Oncology group (GOG) indicate that these agents do not increase the risk 
of post molar trophoblastic disease. In addition the contraceptive method 
didn’t influence the mean HCG regression time. It appears that oral 
contraceptives may be safely prescribed after molar evcuation during the 
entire interval of hormonal followup. 
 
Host Related Factors:- 
 
 There is limited information on other possible etiological risk 
factors for GTD such as smoking, alcohol consumption, diet, 
socioeconomic status. 
 
 3 studies showed relative risk greater than 2 for HM and 
choriocarcinoma in women who smoked, with a trend towards increased 
risk with longer duration of the habit (relative risk for years 4.2;95%). CI 
1.6 – 10.8) (Baltazar JC et al, LA Vecchia C et al)36. However two other 
studies found no association between smoking and GTD (Messerti – ML 
et al) (or) CHM (Bronton LA et al).  
 
An association between high alcohol intake and GTD was found in 
a study from the USA (relative risk 2.1 >95%, 1.2-3.9 for >53 drinks / 
week, Brinton LA et al). But no association was reported in a study on 
HM from Italy (Parazzini et al)41. 
 
Diet has also been suggested to have an etiological role owing to 
the high frequency of GTD in some regions, where malnutrition is 
common. However the result of most been inconsistent. A protective role 
of a high betacarotene intake has been suggested in a study from Italy. 
(Parazzini             et al relative risk 0.2) 41. This evidence was not 
confirmed in another study on PHM from USA. (Berkowitz RS et al)12.  
 
Clinical Presentation:- 
 
1. Vaginal Bleeding:- 
  
 Vaginal bleeding is the most common symptoms causing patients 
to seek treatment for complete molar pregnancy, previously it was 
reported to occur in 97% of the cases, where as currently it is reported to 
occur in 84% of patients (17). Because vaginal bleeding may be 
considerable and prolonged , one half of these patients had anemia 
(hemoglobin < 10gms / 100ml). Currently anemia is present in only 5% 
of patients. 
 
2. Excessive Uterine Size:- 
 
 Excessive uterine enlargement relative to gestational age is one of 
the classic signs of complete mole, although it was present in only about 
one half of patients. Currently excessive uterine size occurs in 28% of 
patients. 
 
3. Pre-Eclampsia:- 
 
 Pre eclampsia was once observed in 27% of patients with a 
complete mole. Preeclampsia is now reported in only 1 of 74 patients 
with complete mole at the initial visit (17). Although preeclampsia is 
associated with hypertension, protinuria and hyperreflexia, eclamptic 
convulsions rarely occur. Preeclampsia develops almost exclusively in 
patients with excessive uterine size and markedly elevated HCG levels. 
Hydatidiform mole should be considered whenever preeclampsia 
develops early in pregnancy. 
 
 
4. Hyperemesis Gravidorum:- 
 
 Hyperemesis is requiring antiemetic (or) intravenous replacement 
therapy occurs in one fourth of the women with a complete mole, 
particularly those with excessive uterine size and markedly elevated HCG 
levels. Severe electrolyte disturbances may develop and require treatment 
with parental fluids. Currently only 8 % of the patients have hyperemesis. 
 
5. Hyperthyrodism:- 
 
 Clinically evident hyperthyrodism is observed in approximately 
7% of patients with a complete molar gestation. Galton et al (13) repored 
11 patients whose thyroid function test values were elevated before molar 
evacuation and the thyroid function test values rapidly returned to normal 
in all patients after evacuation. 
 
 
6. Trophoblastic Embolization:- 
 
 Respiratory distress developed in 2% of patients with a complete 
mole in the past, but currently rarely occurs. Respiratory distress is 
usually diagnosed in patients with excessive uterine size and markedly 
elevated HCG levels. 
 
 
 
 
7. Theca Lutin Ovarian Cysts:- 
 
 Prominent theca lutin ovarian cysts (6cm in dia meter) developing 
in about one half of patients with complete mole. After molar evacuation 
theca lutin cysts normally regressed spontaneously within 2 to 4 months. 
 
Partial Hydatidiform Mole:- 
 
 Patients with partial hydatidiform mole usually do not have the 
dramatic clinical features characteristics of complete molar pregnancy. In 
general these patients have the signs and symptoms of incomplete or 
missed abortion, and the partial mole can be diagnosed after histological 
review of the tissue obtained by curettage (Novak 14th edition)38. 
 
In a survey of 81 patients with a partial mole presented with the following 
features:- 
 
 Vaginal bleeding     -  72.8% 
 
 Excessive Uterine enlargement   - 3.7% 
 
 Pre eclampsia     - 2.5% 
 
None had theca lutein cysts, hyperemesis (or) hyperthyrodisim. Pre 
evacuation HCG levels were measured in 30 patients and were higher 
than 1,00,000 mIU/ml in only 2 patients (6.6%).  
 
Study from India in 2003 patients presented with the following clinical 
features. 
 
Bleeding PV     –  93.5% 
 
Hyperemesis & Hypertension   –  1% 
 
Asymptomatic     –  <10% 
 
 
Treatment: (Practical Gynec. Oncology – Jonarthan Berck 4th 
Edition)38
 
 After molar pregnancy is diagnosed, the patient should be 
evacuated carefully for the presence of associated medical complications, 
including preclampsia, hyperthyrodisim, electrolyte imbalance and 
anemia. After the patient has been stabilized, a decision must be made 
concerning the most appropriate method of evacuations. 
Suction Curettage:- 
 
 Blood should be transfused if required, Suction Curettage is 
preferred method of evacuation, regardless of uterine size in patients who 
desire to preserve fertility. It involves the following steps. 
 
1. Cervical dilation :- Induction of abortion of a molar pregnancy with 
prostaglandins is effective in dilating the cervix prior to evacuation. 
Prostaglandin vaginal persary for ripening the cervix (or) 
cervicalgel 0.5mg denoprossone (PGE2) may be warranted in a few 
cases in whom cervical dilation with metal dilator may be 
undesirable (or) difficult due to tight cervical OS. 
2. Oxytocin infusion: This is begin in the operating room before the 
induction of anesthesia (oxtocin dip of 10-20 units (or) more in 
500ml of 5% glucose).  
3. Suction Curettage: Within a few minutes of commencing suction 
curettage, the uterus may decreases dramatically in size and the 
bleeding is usually well controlled. If the uterus is more than 14 
weeks in size, one hand may be placed on top of fundus and the 
uterus massaged to stimulate uterine contraction and reduced the 
risk of perforation. 
4. Sharp Curettage: When suction evacuation is though to be 
complete, sharp curettage is performed to remove any residual 
molar tissue. The specimens obtained on SE and sharp curettage 
should be submitted separately for pathological review. 
Hysterectomy – if the patient diseases surgical stabilization & 
above 40 years hysterectomy may be performed with the mole in 
situ. The ovaries may be preserved at the time of surgery, even 
though theca lutein cysts are present. Prominent ovarian cysts may 
be decompressed by aspiration. 
 
 
Prophylatic Chemotherapy: 
 
 The use of prophylatic chemotherapy at the time of evacuation of a 
complete mole is controversial. The debate conerns the wisdom of 
exposing all patients to potentially toxic treatment, when only 
approximately 20% are at risk for development of persistent GTN. 
 
 In a study of 247 patients with complete molar pregnancy who 
received a single course of actinomycin Dprophylactically at the time of 
evacuation, local uterine invasive subsequently developed in only 10 
patients (4%) and in no case did metastasis occur. Prophylatic 
chemotherapy, therefore, not only prevented metastasis, it reduced the 
incidence and morbidity of local uterine invasion. Therefore prophylaxis 
may be particularly useful in the management of high risk complete 
molar pregnancy, especially when hormonal follow up is unavailable (or) 
unreliable. But in our instution we are not using prophylactic 
chemotherapy. 
 
Follow up (Novak 14th Edition)38. 
 
 After molar evacuation, patients should be monitored with weekly 
determinations of B subunit HCG levels, until these levels are normal for 
3 consecutive weeks, followed by monthly determinations until the levels 
are normal for 6 consecutive months. The average time to achieve the 
first normal HCG level after evacuation is about 9 weeks. At the 
completion of follow up, pregnancy may be undertaken. After a patient 
achieves is non detectable HCG levels, the risk of developing tumor 
relapse is very low and may approach zero. 
 
It appears that oral contraceptives may be used safely after molar 
evacuation, during the entire interval of hormonal follow up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
 
 
 
 
The study aims to analyse the epidemiological factors of molar 
pregnancy and its varied clinical presentation in the Institute of Obstetrics 
and Gynaecology, Govt. Hospital for women and children, Egmore, 
Chennai. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
Place of Study: 
 
 The study was conducted in the Department of Medical Oncology 
and department of Obstetrics and Gynaecology, Government Hospital of 
Women and Children, Egmore, Chennai. 
 
Period of Study: 
 
 The cases registered in the dept of medical oncology from July 
2006 – July 2007 were taken up for analysis / study. 
 
Sample Size: 
 
 The patients who were studied during this period 110 patients. 
Normal Deliveries during the same period was taken as control group. 
 
Methods: 
 
 This is an observational and a prospective study in patients with 
vesicular mole. (Symptoms, USG, BHCG level, HPE and Macroscopic 
specimen appearance). Excluded all cases referred for oncology care to 
IOG. 
 
The patients under the study were admitted in IOG and undergone 
suction evacuation in this Institute, and its sister Institute KGH 
Triplicane. All were registered and followed up in the Department of 
Medical Oncology IOG, Chennai.   
 
This study was conducted over a period of one year in the medical 
oncology department of IOG. The patients were inter viewed, examined 
and their medical records were checked thoroughly. All relevant factors 
such as age, parity gravida socioeconomic status, general condition, age 
of menarche were noted. Apart from this their previous obstetric history 
like the previous pregnancy and their outcome and previous history of 
vesicular mole was also noted. 
 
The clinical features that were analysed are bleeding PV, 
Abdominal pain, hyperemesis, the gestational age at the time of diagnosis 
and the uterine size in relation to gestational age. Details of complication 
and abnormal presentation are noted. 
 
Serial estimation of serum BHCG and the time taken for the serum 
BHCG to normalized to <5 MIU was noted. The ultrasonographic 
findings lik the status of ovaries (the lutein cysts) and the patients 
diagnosed asymptomatically with only USG findings were analyzed. The 
chest x-ray findings were noted. The details of patients follow up at the 
medical Gyneacology department was noted and combined. 
 
Statistical Analysis: 
 
 Statistically the chi squared test was used to define the significance 
of differences between groups. 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION 
 
The observational study is a hospital based one and not population based. 
 
Incidence: 
During the study period there was a total of 19,944 deliveries in IOG. 
 Total no of cases of GTD during this one year is 110 of which 20 
cases were treated outside and sent here for oncology care. Hence not 
included in this study. So total number of cases molar pregnancy works 
upto 90, shows the distribution of molar pregnancy in the study. 
 
TABLE – 1 
 
Total No of cases of molar pregnancy: 90 
 
 
Complete hydatidiform 
mole 
 
81 (out of this 10 remain as 
PTD) 
 
Partial hydatidiform mole 
 
9 
 
Chorio Carcinoma 
 
- 
 
Persistent trophoblastic 
disease 
 
10 
 
 
 
Incidence of Molar Pregnancy in IOG 
 
4.51 / 1000 Deliveries 
Above table shows the incidence of molar pregnancy as 4.51 per 
1000 deliveries our Institute is a tertiary referral center. The above datas 
are hospital based and not a population based. 
Referral: 
 20 cases of GTD (PTD and choriocarcinoma and (invasive mole) 
had undergone suction and evacuation  (or) dilation and curettage (or) 
hysterectomy outside, long time ago and referred for complications. 
 Of the 20 cases referred 3 were referred as cases of 
choriocarcinoma with only 2 had HPE report. These patients were not 
included in the study.  
AGE:- 
 
Age distribution of molar pregnancy in IOG is as follows:- 
 
TABLE-3 
 
 
Age 
 
No of 
Cases 
 
% 
 
 
<20 
 
16 
 
17.78% 
 
21-30 
 
64 
 
71.11% 
 
31-39 
 
10 
 
11.11% 
 
Most of the cases of molar pregnancy presented at IOG were 
between the Age Group 21-30 years which is about 71.11%, 17.78% of 
cases were below the age of 20 years. No cases registered were beyond 
40 years of age. Only about 10 cases registered between 31-40 years. 
 ANTECEDENT PREGNANCY:- 
 
TABLE-4 
 
 
Antecedent Pregnancy 
 
No of 
Cases 
 
% 
 
 
Primi 
 
36 
 
40% 
 
G2 ( full term) 
 
20 
 
22.22% 
 
G3 ( full term) 
 
9 
 
10% 
 
G4 (full term) 
 
3 
 
3.33% 
 
Abortion 
 
18 
 
20% 
 
Previous Molar 
Pregnancy (included in 
gravida) 
 
2 
 
2.22% 
 
G6 
 
2 
 
2.22% 
 
 
Most of the patients in this study were primi i.e., about 40%. Only 
3 cases of fourth gravida and 2 cases of 6th gravida were there in our 
study. About 20% of patients, molar pregnancy is preceded by abortions. 
Two patients had history of previous molar pregnancies. 
 
 
 
 
 
 
 
 
TABLE – 5 
 
BLOOD GROUP:- 
 
 
Blood Group
 
No 
 
% 
 
O 
 
31 
 
34.44 
 
B 
 
29 
 
32.22 
 
AB 
 
6 
 
6.67 
 
A 
 
24 
 
26.67 
 
 
Most of the patients blood group were O about 31 patients 
(34.44%). 32.22% belonged to Group B. 26.27% belonged to Group A 
and 6.67% of the patients belonged to Group AB. As the spouses blood 
group, could not be followed the combination could not be studied. 
 
Host related Factors:- 
 
 The patients in this study group belong to all castes and creeds as 
our institute served the population of not only Tamilnadu but also the 
adjoining state of AP & Karnataka. 
 
 Majority belonged to low socioeconomic status of class IV and V 
with >90% them being literate. 
 
 Patients in this study were either pure vegetarians (<10%) (or) 
taking mixed diet, i.e. occasional non vegetarian diet once (or) twice in a 
week. All of them took less of fruits and vegetables. None of the patients 
gave history of smoking (or) consuming alcohol.  Less than 2% of 
women gave H/o using OCP. 
 
Hemoglobin:- 
 
 More than 60% of the patients had Hb more than 10gms/dl ranging 
from 6.5 to 13.5 with an average of 10gm/dl. This shows a reduction of 
patient presenting with Anemia. 
 
Menarche:- 
 
 The average age of menarche the patients with molar pregnancy 
was 13 years, ranging from 11-16 years and most of them i.e. more than 
90% had normal menstrual cycles. 
 
Clinical Features:- 
 
TABLE-6 
 
Clinical Presentation:- 
 
 
Clinical 
Presentation 
 
No 
 
% 
 
Bleeding PV 
 
65 
 
72.22% 
 
Passing Vesicles 
 
3 
 
3.33% 
 
Spotting 
 
12 
 
13.33% 
 
USG 
 
11 
 
12.22% 
 
Elevated BHCG 
 
2 
 
2.22% 
 
Other Presentation  
 
1 (thyrotoxicosis) 
 
 
PIH 
 
2 
 
 
 
This study shows 72.22% presented with bleeding PV and a few 
3% had H/o passing vesicles 13.33% of the patients presented with 
minimal bleeding of just spotting. 
 
Interesting features of the clinical presentation was that 11 patients 
in our hospital were admitted with no symptoms of molar pregnancy but 
only with ultrasonographic evidence and elevated βHCG level. They 
were diagnosed to have molar pregnancy incidentally when they 
underwent routine USG in their first trimester of pregnancy. In coming 
years we are likely to encounter more number of such asymptomatic 
cases of molar pregnancies.   
 
The prognosis of these asymptomatic cases were excellent, they all 
had βHCG values less than 1lakh IU unit except one case, and all cases 
including the one with high βHCG level normalize with in average period 
of 6 wks and none of them had persistent trophoblastic disease. 
 
Only two cases presented with preclampsia, and one of the patient 
presented with features of thyrotoxicosis. 
 
 
Period of Amenorrhoea: 
TABLE-7 
Period of 
Amenorrhoea No % 
2MA 19 21.11% 
3MA 31 34.44% 
4MA 25 27.80% 
5MA 13 14.44% 
6MA 2 2.22% 
 
Average no of Weeks: 12.86 weeks 
 
 More than 50% of the patients presented at 3 month and 4 months 
of amenorrhoea and only 2 patients presented at 6 months of 
amenorrhoea and the average period of amenorrhoea when patients 
presented was 12.86 weeks. 
TABLE-8 
Uterine Size in relation to Gestational Weeks 
Uterine size No % 
Corrosponding 30 33.33% 
Big (more) 45 50% 
Small (less) 15 16.67% 
 
The uterine size corresponds to the period of amenorrhoea in 
33.33% of patients. It was bigger than the period of amenorrhoea in 50 % 
of patients and 16.67% had uterine size smaller than the period of 
amenorrhoea. Of 45 patients with large uterine size about 14 had BHCG 
value more than 1Lakh mIU/Lit. 
 
USG:- 
 
TABLE-9 
 
 
USG 
 
No 
 
% 
 
Theca lutein cyst 
 
24 
 
26.67% 
 
Bilateral Theca lutein 
cyst 
 
18 
 
75% 
 
Unilateral Theca lutein 
cyst 
 
6 
 
25% 
 
  
USG is the gold standard for the diagnosis of vesicular mole with 
typical “snow storm” appearance. The patients in this study were all 
subjected to sonographic examination either with symptom (or) 
Asymptomatically. 
 
 24 patients of this study i.e. 26.67% had theca lutein cysts of which 
6 were unilateral and 18 had Bilateral lutein cysts.  10 patients who had 
persistent trophoblastic disease 4 had theca lutein cysts. 
 
 One patient was diagnosed to have ? cornual pregnancy (Lt 
Cornua) with partial molar changes, the patient had bleeding PV on & off 
for 1 month duration, done suction evacuation – HPE report showed that 
cornual pregnancy was a partial mole. There was problem in curetting the 
uterus because of cornual location, hence injection methotrexate given. 
Her βHCG value normalized with in 8 weeks. 
 
One of the Patient had twin gestation of which one was a molar 
pregnancy, patient became symptomatic at 3 months of amenorrhoea with 
C/o of spotting PV, the USG  done and diagnosed of having twin, one of 
which is vesicular mole, hence pregnancy terminated and she was 
followed up. 
 
Chest x-ray:- 
 
 All patients were subjected to chest x-ray before suction evacuation 
and none of them had any abnormality like metastasis (or) pulmonary 
embolism. 
 
Treatment:- 
 
 Patients diagnosed to have molar pregnancy were admitted. Basic 
investigations like Hb, PCV, Urine Analysis, Renal and Hepatic 
parameters were taken patients blood grouping and Rh typing done for all 
cases. An USG to confirm diagnosis, Chest X-ray and ECG for 
Anaesthetic purpose were taken. Patient had their serum βHCG done 
outside whenever affordable. About 55% of the patients had their 
preevaluation βHCG done outside. 
 
 If the patients had profuse bleeding, on examination the OS was 
open, they underwent emergency suction evacuation. Others underwent 
elective suction evacuation. Their cervix was softened and dilated with 
either misoprostal (PGE1) 200-400 μg vaginal tablets (or) cerviprime gel 
(PGE2) 0.5mg (or) osmotic dilators like laminaria tents were used. 
 
 During the procedure a unit of Blood cross matched and kept ready 
for transfusion. Whenever need arises depending on the bleeding during 
the procedure (or) whenever the patients pre evacuation hemoglobin was 
low, blood transfusion was given. Suction evacuation done under IV 
sedation. Oxytocin 20 units in 500ml of 5% dextrose started in all cases 
prior to giving IV Anaesthesia after cervical dilatation. At the end of the 
procedure 0.2mg of IV methergine given. All Rh negative mothers were 
given Anti D immunoglobulin depending on the period of Amenorrhoea 
150 μg IM. 
 
None of the patients developed any anaesthetic (or) procedural 
complications like shock, haemorrhage perforation (or) embolism etc. 
 
 
 
 
 
Follow Up: 
TABLE-10 
 
βHCG Levels:- Follow Up after Evacuation. 
 
 
Weeks 
 
No of 
Cases 
 
% 
 
Average 
Weeks 
 
<9wks 
 
33 
 
52.38% 
 
6.9wks 
 
9-12wks 
 
20 
 
31.25% 
 
11.15wks 
 
>13-16wks 
 
6 
 
9.52% 
 
15.3wks 
 
>16wks 
 
5 
 
7.93% 
 
18.4wks 
 
 
83% have average of 7.68 wks for βHCG to normalize, patients 
were asked to come weekly till their βHCG values normalize for three 
consecutive weeks and then given monthly follow up for one year. 
Patients were put on OCP and they were asked to do βHCG level outside. 
Each time they came for follow up, patients were subject to abdominal 
examination, sonographic examination, and if needed chest x-ray was 
taken. If patients could not do βHCG outside, they were subjected to 
urine βHCG examination in dilution. Serum βHCG value of <5m IU unit 
was taken as normal. 
 
 Only about 71% of the patients had serum βHCG values done 
outside in their follow up. Another 5% of the patient underwent urine 
βHCG examination in dilution. In 52% of the cases βHCG normalizes 
within average of 6.9 weeks, and 31.25% of cases βHCG normalized 
within 12 weeks. Only 17% of cases βHCG normalized after 16weeks of 
followup. 83% of patients studied had their βHCG normalized within 
average period of 6.9 weeks. 
 
 
 
TABLE-11 
 
Persistant Trophoblastic Disease:- 
 
 
Method of Diagnosis 
 
No of PTD
 
% 
 
Plateauing of βHCG 
 
8 
 
80% 
 
Presence of symptoms 
(irregular vaginal 
bleeding) 
 
2 
 
20% 
 
Invasive Mole 
 
5 
 
50% 
 
 
 
TABLE-12 
 
Persistant Trophoblastic Disease 
 
Drug Taken Complete Remission Partial Remission 
Methotrexate wkly                        7 Cases                                        3 
Cases 
With Folic acid 
 
 
 Actinomycin - D                           2 Cases                                         1 
Case 
 
 
 
Multi Drug                                     1 Case 
 
Etoposide, Cisplatin 
 
 
Persistent Trophoblastic Disease:- 
 
 Of 90 cases 10 patients went in for persistant trophoblastic disease 
which is about only 11.1% out of 10 cases of PTD – 8 cases are 
diagnosed by persistently increased βHCG levels, and 2 cases are 
diagnosed as PTD due to persistence of symptoms. Out of 10 cases of 
PTD – five cases are invasive moles. 
 Out of 10 cases of persistent trophoblastic disease, seven cases the 
βHCG level normalizes with single agent chemotherapy regimen. 
(Methotrexate + folic acid weekly) with average of 12.28 weeks. 
 
In the remaining 3 cases, 2 cases βHCG normalized with 
Actinomycine – D. In one case of PTD diagnosed at 10 weeks after 
evacuation due to persistently high βHCG – the Methotrexate regimen 
started,  after 2 weeks of starting Methotrexate – due to plateauing of 
βHCG – Actinomycin – D added again due to persistence of βHCG – 
Cisplatin + Etoposide regimen started, after 6 weeks of starting this 
combination Chemotherapy βHCG normalized. 
RESULTS AND ANALYSIS 
 
As our institute is a tertiary referral center, the below data are 
hospital based data and not a population based. 
 
Incidence: 
 
 During the study period there was a total of 19,944 Deliveries in 
Institute of Obstetrics and Gynaecology.. Total no of Gestational 
Trophoblastic diseases during this one  year is 110 of which 20 cases 
were referred from outside with complications treated outside. Hence not 
included in this study. The total number of molar pregnancy hence works 
upto 90. Table 1 shows the distribution of molar pregnancy in IOG. 
 
TABLE-1 
 
Total No of cases of Molar pregnancy –   90 
 
Complete Hydatidiform mole   –   81 (out of this 10 remains as 
PTD) 
 
Partial hydatidiform mole   – 9 
 
Choriocarcinoma     –   - 
 
Persestant trophoblastic Disease  –  10  
 
Incidence of Molar Pregnancy in IOG. 
 
4.51 / 1000 Deliveries  
 
Table 2 shows the incidence of molar pregnancy in IOG during the 
study period as 4.51 / 1000 deliveries. The study by Kumar et al from 
New Delhi29 shows the incidence of 1.31 / 1000 live births. This variation 
in the incidence rate in molar pregnancy may be due to the differences 
between reporting population and the hospital based data. 
 
The regional differences in the frequency of hydatidiform mole 
have been attributed to genetic and environmental factors (or) the 
interaction of both. 
 
This high incidence when compared to incidence in North America 
and UK (2 in 1000) can be attributed to the factor that Asian descent and 
especially Indian’s (Cheah PL et al Malaysia, Wales study) are at 
increased risk for GTD. As it is suggested that GTD occur especially in 
rice eaters (Jeffcoate)30. Hence the increase in incidence of molar 
pregnancy among our population, whose stable food is rice. 
 
When compared to previous years incidence in IOG – which was 
about 4.8 in 2004, 5 in 2005, the incidence of molar pregnancy has come 
down. This is due to literacy, awareness, socioeconomic improvement 
availability of medical facilities, their easy approachability and also due 
to increased rate of permanent method of sterilization. This is similar to a 
Korean study by KIM SJ et al 199831 states that Koreas socioeconomic 
improvement in recent decades also contributed to decrease in the 
incidence of GTD and increased survival rates. 
 
Referral:- 
 
 As our’s was a tertiary referral center, 80% of the cases were 
diagnosed outside as vesicular mole and referred early without any 
intervention. These cases subsequently underwent suction evacuation, 
registered and followed up. 
 
 20 cases of GTD (PTD, Choriocarcinoma and invasive mole) who 
had undergone suction evacuation (or) dilatation and curettage (or) 
hysterectomy outside and then referred here. Of the 20 cases referred 
from outside 3 were found to be choriocarcinoma. All these patients were 
invariably treated with chemotherapy and once remission occurred they 
were followed up with ocpills. Their morbidity (more days of hospital 
stay) & mortality was definitely higher compared to the study group. 
 
 
The Age Distribution  of molar pregnancy in IOG is as follows. 
 
TABLE-3 
 
 
Age 
 
No of Cases 
 
% 
 
<20 
 
16 
 
17.78% 
 
21-30 
 
64 
 
71.11% 
 
31-40 
 
10 
 
11.11% 
 
 
Most of the cases of molar pregnancy presented at IOG were 
between the age group of 21-30 years i.e. about 71.11%. And 17.78% of 
cases presented at earlier age of less than (or) equal to 20 years. No cases 
registered were beyond the age of 40 years. 
 
The age specific distribution of patients shows most of the patients 
belongs to age group 21-30 years. Average age was 24.56 years. The 
fertility at the National level which reaches maximum at 20-25 age group, 
which was reflected in our data. 
 
 
 
 
 
AGE DISTRIBUTION OF MOLAR PREGNANCIES IN IOG
17.78%
71.11%
11.11%
<20
21-30
31-40
 
Maternal age is a well estabilized risk factor for both HM & 
Choriocarcinoma with woman younger than 20 and particularly woman 
older than 40 years.shows stronger risk (Lancet 2003). This study did not 
have patients above 40 years, but there were 17.8% of cases below the 
age of 20 years. 
 
 
TABLE - 4 
 
Age Group in 
Years 
Study Group 
90 
Control Group 
19944 
Differences in two 
groups 
 
<20 years 
 
14 (15.6%) 
 
4432 (22.22%) 
 
Z1.38  P0.17 
NS 
 
21-29 years 
 
67 (74.4%) 
 
14512 (72.76%)
 
Z0.23  P0.82  
NS 
 
> 30 years 
 
9 (10%) 
 
1000 (5%) 
 
Z1.96  P0.05 
S 
 
NS  –  Not Significant 
S  –  Significant  
 
Above table shows significant risk of about 1.96 times was found in 
women more than 30 years. 
Antecedent  Pregnancy:- 
 
TABLE - 5 
 
Antecedent Pregnancy No of Cases % 
Primi 36 40% 
Gravida 2  20 22.227% 
Gravida 3 9 10% 
Gravida 4 3 3.33% 
Abortion 18 20% 
Previous molar 
pregnancy (included in 
gravida) 
2 2.22% 
Gravida 6 2 2.22% 
 
 
40%
22.23%
10%
3.33%
20%
2.22% 2.22%
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DISTRIBUTION OF MOLAR PREGNANCY AMOUNG VARIOUS GRAVIDA IN IOG
 
 
 
1. Abortions:- 
 
 18 out of 90 cases of molar pregnancy i.e. 20% gave a history of 
previous abortion. Abortion was associated with a modest increased risk 
of GTD in at least 7 studies. 
 
 Similar finding was seen in the study group from Delhi Where 
36.9% of the patients with GTD had previous history of abortion as 
against 9.3% of the patient who had normal deliveries in their institute. 
 
 This shows the likelihood of abnormal oocyte to be fertilized is 
increased in those woman with previous history of abortions (or) these 
abortions were actually undiagnosed molar pregnancies. 
 
 
 
2. Previous Molar Pregnancy:- 
 
 This study revealed that about 2.22% of the patients with molar 
pregnancy gave history of previous molar pregnancy. A previous history 
of molar pregnancy is the second  best established risk factor (Buckley et 
al)17 the risk of Hydatidiform mole in a subsequent conception is about 
1% (Buckley JD et al, Matsui et al). 
 
 This study also reflects a similar finding of 1-2, increased risk of 
developing molar pregnancy in patients with history of previous molar 
pregnancy. 
 
Previous Pregnancy:- 
 
 About 40% of the patients in this study were primigravida and 20% 
of the patients were 2nd gravidas with Antecident term deliveries. The 
effect of the reproductive history on the risk of GTD remains unclear 
(Lancet 2003). As GTD are strongly associated with pregnancy the 
choice of adequate comparison group is difficult. The increase incidence 
of molar pregnancy in primigravida may be attributable to the younger 
age of these patients i.e. 20% were below the age of 20 years. Similarly 
the incidence increased in multiparous may also be attributed to their 
increasing age, where chances of fertilization of abnormal oocyte  is 
always increased. 
 
TABLE - 6 
 
Distribution of Molar Pregnancy among  various  Gravidas: 
 
Previous 
Pregnancy 
Study Group 
90 
Control Group 
19944 
Differences in P 
value 
 
Primi 
 
36 (40%) 
 
10218 (51.2%) 
 
Z=2.02, P = 0.04 
S 
 
Gravida 2 
 
20 (22.22%) 
 
7326 (36.73%) 
 
Z=2.75, P=0.07 
S 
 
Gravida 3 
 
9 (10%) 
 
1902 (9.54%) 
 
Z=0.00, P=1 
NS 
 
Gravida 4 
 
3 (3.33%) 
 
402 (2.01%) 
 
Z=0.16, P=0.87 
NS 
 
Gravida 5 
 
- 
 
66 
 
- 
 
NS  - Not Significant 
S  - Significant 
 
In comparison with control group and the study group, the P value 
in primigravida is 0.04 which is significant. And also in second gravida 
study group (22.22%) when compared with control group (36.73%) the P 
value is 0.07, significant. 
 
 
Blood group Distribution among patients with molar pregnancy. 
 
TABLE - 7 
 
Blood 
Group No % 
O 31 34.44 % 
B 29 32.22% 
AB 6 6.67% 
A 24 26.67% 
 
 
Most of the patients blood group was O about 31 patients 
(34.44%). 32.22% belonged to Group B. 26.67% belonged to Group A 
and 6.67% of the patients belonged to Group AB. As the spouses blood 
group, could not be followed the combination could not be studied. 
Hence no conclusive implication of this information could be associated 
with molar pregnancy. 
BLOOD GROUP DISTRIBUTION AMOUNG PATIENTS 
WITH MOLAR PREGNANCY
34.44%
32.22%
6.67%
26.67%
O
B
AB
A
 
 
Host Related Factors: 
 
 The Patients in this study group belong to all castes and creeds as 
our institute served the population of not only Tamilnadu but the 
adjoining state of AP and Karnataka. 
 
 Majority belonged to low socioeconomic status of class IV, V with 
>90% of them being literate. 
 
 Patients in this study were either pure vegetarians  (<10%) (or) 
taking mixed diet i.e. occasional non vegetarian diet once (or) twice in a 
week. All of them took less of fruits and vegetables. None of the patients 
gave history of smoking (or) consuming alcohol. Less than 2% of woman 
gave H/o using oral contraceptive pills. 
 
Haemoglobin:- 
 
 More than 60% of the patients had Hemoglobin more than 
10gms/dl ranging from 6.5 to 13.5 with an average of 10gms/dl. This 
shows a reduction of patient presenting with anaemia. 
 
 
 
 
 
 
 
 
Menarche:- 
 
 The average age of menarche the patients with molar pregnancy 
was 13 years, ranging from 11-16 years and most of them i.e. more than 
90% had normal menstrual cycles. 
 
TABLE - 8 
 
Clinical Presentation:- 
 
Clinical Presentation No of Cases % 
Bleeding PV 65 72.22% 
Passing Vesicles 3 3.33% 
Spotting 12 13.33% 
USG 11 12.22% 
Elevated βHCG  2 2.22% 
Other Presentation 1 (Thyrotoxicosis)  
PIH 2  
 
 
This study shows 72.22% presented with bleeding PV and few 3% 
had H/o passing vesicles 13.33% of the patients presented with minimal 
bleeding, of just spotting. 
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CLINICAL PRESENTATION OF MOLAR PREGNANCY IN IOG
 
 
Interesting Feature of the clinical presentation was that 11 patients 
in our hospital were admitted with no symptoms of molar pregnancy but 
only with ultrasonographic evidence and elevated βHCG level. They 
were diagnosed to have molar pregnancy incidentally when they 
underwent routine USG in their first trimester of pregnancy. Incoming 
years we are likely to encounter more number of such asymptomatic 
cases of molar pregnancy. The study conducted in USA about 50% of 
patients presented asymptomatically. (Pennsylvania 1999). A finding 
from a study by Kumar et al from New Delhi29, India, Showed about 
6.5% of cases which presented without any symptoms. 
 
The Prognosis of these Asymptomatic cases were excellent, they 
all had βHCG values less than 1 lakh IU unit except one case and all 
cases including the one with high βHCG level normalized within the 
average period of 6 weeks, and none of them had persistent trophoblastic 
disease. 
 
Only two cases presented with preeclampsia, and one of the patient 
presented with features of thyrotoxicosis, all the three relieved of 
symptoms after  evacuation. Even the number of patients with Anemia 
was comparatively less. All these point to the better medical facilities 
available in a developing country like India. 
 
PERIOD OF AMENORRHEA 
 
TABLE – 7 
 
Period of Amenorrhea No of Cases % 
2MA 19 21.11% 
3MA 31 34.44% 
4MA 25 27.80% 
5MA 13 14.44% 
6MA 2 2.22% 
 
 
Average No of weeks: 12.86 weeks- 
 
 More than 50% of the patient presented at third and fourth month 
of Amenorrhea and only two patients presented at 6MA. The average 
period of Amenorrhea when patients presented at IOG with molar 
pregnancy was 13 weeks (12.86wks). 
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TABLE - 8 
 
Uterine Size in Relation to the Period of Amenorrhea 
 
Uterine Size No of Cases % 
Corresponding 30 33.33% 
Big (more) 45 50% 
Small (less) 15 16.67% 
 
 
 
The uterine size corresponds to the period of Amenorrhea in 
33.33% of patients. It was bigger than the period of Amenorrhea in 50% 
of patients and 16.67% of patients had uterine size lesser than the period 
of Amenorrhea. Of 45 patients with large uterine size about 14 had 
βHCG value more than 1 lakh mIU/ml. The βHCG was elevated with 
large uterine size. 
 
UTERINE SIZE IN RELATION TO THE PERIOD OF 
AMENORRHEA
33.33%
50%
16.67%
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TABLE - 9 
 
 
USG 
 
No of Cases
 
% 
 
Theca Lutein Cyst 
 
24 
 
26.67% 
 
Bilateral Theca Lutein 
Cyst 
 
18 
 
75% 
 
Unilateral Theca Lutein 
Cyst 
 
6 
 
25% 
 
 
USG is the gold standard for the diagnosis of vesicular mole with 
typical “snow storm” appearance.  
 
The patients in this study were all subjected to sonographic 
examination either with symptoms (or) Asymptomatically. 
 
24 patients of this study i.e. 26.67% had theca lutein cysts of which 
6 were unilateral and 18 had bilateral theca lutein cysts. One patient was 
diagnosed to have corneal pregnancy (left cornual) with partial molar 
changes, The patient had bleeding PV on & off for 1 month duration, 
undergone suction evacuation at IOG. HPE report showed that the 
cornual pregnancy was a partial mole. There was problem in curetting the 
uterus hence injection Methotrexate given. Her βHCG value normalized 
with in 8 weeks. 
One of the patient had twin gestation of which one was a molar 
pregnancy. Patient became symptomatic at 3MA with complaints of 
spotting PV. Hence pregnancy terminated and she was follow up. 
 
Chest X-Ray:- 
 
 All patients were subjected to Chest X-ray before suction and 
evacuation and none of them had any abnormality like metastasis (or) 
pulmonary embolism. 
 
Treatment: 
 
 Patients diagnosed to have molar pregnancy were admitted. Basic 
investigations like Hb%, PCV, Urine analysis, Renal and Hepatic 
Parameters were taken. Patients blood was grouped and typed. An USG 
to confirm diagnosis. Chest X-ray and ECG for anaesthetic purpose were 
taken. Patients had their serum βHCG done outside whenever affordable. 
About 55% of  the patient had their preevacuation βHCG done outside. 
 
If the patients had profuse bleeding, on examination if the OS was 
open, they underwent emergency suction evacuation. Others underwent 
elective suction evacuation. Their cervix was softened and dilated with 
either Misoprostal (PGE1) 200-400 μg vaginal tables (or) cerviprime gel 
(PGE2) 0.5mg (or)Osmotic dilators like laminaria tents were used. 
 
During the procedure a unit of blood cross matched and kept ready 
for transfusion. When ever need arises depending on the bleeding during 
the procedure (or) whenever the patient preevacuation hemoglobin was 
low, blood transfusion was given. Suction evacuation done under IV 
sedation. Oxytocin 20 units in 500ml of 5% dextrose started in all cases 
prior to giving IV anaesthesia. 
 
At the end of the procedure 0.2mg of IV Methergine given. All Rh 
negative mothers were given injection Anti D immuno globulin 
depending  upon the period of Amenorrhea (150μgmIM). 
 
None of the patients developed any anaesthetic (or) procedural 
complications like shock, Haemorrhage perforation (or) embolization etc. 
 
 
TABLE – 10 
 
 
Follow Up:- 
 
βHCG – Follow up after Evacuation. 
 
Weeks No of Cases % Average Weeks 
<9 weeks 33 52.38% 6.9weeks 
9-12 weeks 20 31.25% 11.15 weeks 
13-16 weeks 6 9.52% 15.3 weeks 
>16 weeks 5 7.93% 18.4 weeks 
 
 
83% have average of 7.68 weeks for βHCG to normalize, patients 
were asked to come weekly full their βHCG Values normalize for three 
consecutive weeks and then given monthly follow up for one year. 
Patients were put on OCP and they were asked to do βHCG outside. Each 
time they came for follow-up, patients were subjected to abdominal 
examination, sonographic examination, and if needed X-ray chest was 
taken. If the patient could not do βHCG outside they were subjected to 
urine βHCG examination in dilution.  Serum βHCG value of <5mIU/I 
was taken as normal. 
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Only about 71% of the patients had serum βHCG values done 
outside in their follow-up. Another 5% of the patient underwent urine 
βHCG examination in dilution in 52% of the cases βHCG normalizes 
within average of 6.9 weeks, and 31.25% of cases βHCG normalized with 
in 12 weeks.  Only 17% of cases βHCG normalized after 16 weeks of 
follow up. 83% of patients studied had their βHCG normalized within 
average period of 6.9 weeks. 
 TABLE – 11 
 
Persistent Trophoblastic Disease:- 
 
 
Method of Diagnosis 
 
No of 
PTD 
 
% 
 
Plateauing  of βHCG 
 
8 
 
80% 
 
Persistent of Symptoms 
– Irregular Bleeding PV 
 
2 
 
20% 
 
Invasive Mole 
 
5 
 
50% 
 
 
 
 
TABLE - 12 
 
Total No of Persistent Trophoblastic Disease – 10 
 
Drug Taken Complete Remission Partial Remission 
Methotrexate wkly                        7 Cases                                        3 
Cases 
With Folic acid 
 
 
Actinomycin – D                              2 Cases                                         1 
Case 
 
 
Multi Drug                                        1 Case 
 
Etoposide, Cisplatin 
 
 
Persistent Trophoblastic Disease: 
 
In my study, of 90 cases of GTD, 10 patients went in for persistent 
trophoblastic disease which is about 11.1%. Seckl et al report the 
incidence of a complete hydatidiform transformed into malignant GTN is 
15%. The incidence of PTD in Kumar et al29 study in India is about 
12.12% among GTD cases. Out of 10 cases of persistant trophoblastic 
disease 2 cases were diagnosed as PTD due to complaints – Irregular 
bleeding PV and 8 cases are diagnosed due to persistently increased 
βHCG values. Out of 10 cases of PTD – 5 Cases are invasive moles. 
 
In my study out of 10 cases of persistent trophoblastic disease the 
complete remission occurred in seven cases with only single agent 
chemotherapy (Methotrexate + folic acid weekly regimen) with average 
of 12.28 weeks. 
 
In the remaining 3 cases (30%), 2 cases (20%) complete remission 
occurred with Actinomycin D. In one case of PTD diagnosed at 10 weeks 
after evacuation due to persistently high βHCG – Partial response to 
Methotrexate and due to plateauing of βHCG – Actinomycin added. 
Again due to persistence of high βHCG – cisplatin + etoposide regimen 
started, after 6 weeks of starting this combination chemotherapy the 
patients attained complete remission. 
 
In my study the persistent trophoblastic disease (10 cases – 100%) 
attained complete remission either with single drug therapy (70%) (or) 
multidrug therapy (30%). In the study by Kumar et al New Delhi – By 
early detection and treatment of persistent trophoblastic disease they 
achieved 95.7% complete response and 6.5% partial response.  
 
 
 
 
 
 
SUMMARY 
 The incidence of molar pregnancy over past 10 years had definitely 
come down. The development and improvement of suction 
curettage, termination of pregnancy, contraceptive techniques, 
diagnostic imaging, and biochemical testing have been associated 
not only with a fall in the birth rates, but also with a reduction in 
the incidence of trophoblastic disease. 
 Delayed referral and improper follow up of patients may lead to 
complications. Hence the need to educate the patients on the risk 
factors, early signs and symptoms, the need for prompt referral and 
proper follow up. This will not only bring down the mortality but 
also the morbidity of GTD. 
 In considering the clinical presentation, 12% of the patients were 
asymptomatic diagnosed during their routine Antenatal USG. 
These patients had good prognosis. So with the current widespread 
use of Ist trimester USG, can detect abnormal pregnancy like molar 
pregnancy earlier. 
 The risk of molar pregnancy is more in teenage pregnancy and in 
old age pregnancy. This can be prevented by improving the female 
literacy and adolescent health education. Permanent sterilization 
after completion of family will bring down the old age pregnancy. 
 Blood grouping did not throw any light about the risk of GTD. 
 Patients with uterine size larger than the period of Amenorrhoea 
had higher βHCG levels and increased incidence of PTD. By 
educating the health care providers, and patients about early signs 
and symptoms, of GTD like hyperemesis, first trimester spotting, 
early onset PIH, will help in early referral to higher centers. 
 The need for tertiary care for all patients with molar pregnancy will 
bring down the morbidity of this disease. 
 Careful and reliable Human Chorionic Gonadotrophin monitoring 
is essential for the early detection of post molar persistent 
trophoblastic tumor. 
 If PTD diagnosed during follow up and treated earlier, the low risk 
trophoblastic disease are 100% curable. 
 Gestational trophoblastic tumors have an excellent prognosis if 
diagnosed and treated in time, and the potential for child bearing 
can be maintained. 
 
 
 
 
CONCLUSION 
 
 
 Early pregnancy USG will help in early recognition of abnormal 
pregnancy like molar pregnancy, this will definitely reduce the 
morbidity of this curable disease. 
 
 Proper follow up helped in recognizing the cases of persistent 
trophoblastic disease early. 
 
 If Persistent  Trophoblastic Disease diagnosed during follow up 
and treated earlier, the low risk trophoblastic diseases are 100% 
curable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROFORMA 
 
 
Name:   Age:   IP No: 
 
Socioeconomic Status 
 
Literacy  
 
Nutritional History 
 
Menstrual History   Menorche   Menstrual Cycles 
 
Obstetric History 
 
9 Gravida 
9 Abortions  
9 Previous molar pregnancies 
 
Blood Group 
 
USG 
 
CXR 
 
Hemoglobin 
 
Pre evacuation βHCG 
 
Gestational age at the time of Diagnosis  
Uterine size in relation with gestational age 
 
9 Corresponding Gestational age 
9 Large than the Gestational age 
9 Small than the Gestational age 
 
Previous history of any contraception 
 
Clinical Presentation 
 
9 Bleeding PV 
9 Detected without any complaint 
 
Associated complaints 
 
9 Hyperemesis 
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Follow up 
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Key to Master Chart 
 
 
SE – Suction Evacuation 
CTF – Chemotherapy 
MVA – Manual Vaccum Aspiration 
V.Mole – Vesicular Mole 
PIH – Pregnancy Induced Hypertention 
D&E – Dilatation & Curettage 
PTD – Persistent trophoblastic disease 
RPT Mole – Recurrent Mole 
 
 
 
 
